Modification-Driven Nanocarriers: Ovarian Cancer Cell Membrane- Camouflaged Indoximod/Doxorubicin Co-Delivery Systems for Synergistic Immunochemotherapy.

Among the three primary gynecological malignancies, ovarian cancer has the highest mortality rate, and its onset is often insidious. Despite standard treatments, relapse and drug resistance remain major challenges. Doxorubicin (DOX) is known to induc…

Preview only. Read the full abstract at the source